Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 2 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

1
Player Avatar zzlangerhans (99.80) Submitted: 2/28/2013 1:16:09 AM : Underperform Start Price: $1.30 PPHM Score: +12.93

Looks like I got out from under that last badly-timed red thumb on Peregrine a little quicker than I thought. Am I setting myself up for another one? Part of me wants Peregrine to keep the lights on a few more years so that I can keep riding the waves back into score leadership, which was cruelly stolen from me. Another part of me just wants the company to die so I can stop giving myself migraines trying to follow their soap opera drug trials. I only have a limited amount of time and I need to spend most of it on trade grade stocks, not floating dust particles like Peregrine. Damn you, OCD.

Featured Broker Partners


Advertisement